Fragment-based Drug Discovery Market

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of the market for fragment-based drug discovery and its likely evolution in the short-mid-term and long term.

Chapter 3 provides an introduction to the process of drug discovery and development. In addition, the chapter focuses on the concept of fragment-based drug discovery, highlighting its key advantages and drawbacks. It also features a brief discussion on the opportunities and the likely future trends in this field. 

Chapter 4 provides a detailed overview of the current market landscape of fragment-based drug discovery, including information on library and service providers, type of product (library and technology), type of service offered (fragment screening and fragment optimization), type of technique used (X-ray crystallography, nuclear magnetic resonance, surface plasmon resonance, and other screening techniques), other services offered (target identification / validation, hit identification, hit-to-lead / lead generation and lead optimization) and end user (industry players and non-industry players).

Chapter 5 includes detailed profiles of the companies providing library and services for fragment-based drug discovery (shortlisted on the basis of the service portfolio and number of fragment screening techniques offered). Each profile features a brief overview of the company, its financial information (if available), fragment-based library and service portfolio, information on other drug discovery services, recent developments and an informed future outlook.

Chapter 6 features an elaborate analysis of the partnerships that have been inked among various stakeholders in this domain, during 2015-2020. It includes a brief description of partnership models (such as research and development agreements, mergers and acquisitions, product development and commercialization agreements, distribution and supply agreements, service alliances, and commercialization agreements) adopted by the stakeholders.

Chapter 7 provides a detailed acquisition target analysis, taking into consideration the historical trend of the activity of the companies that have acquired other firms since 2015, and offering a means for other industry stakeholders to identify potential acquisition targets.

Chapter 8 provides an insightful competitiveness analysis of fragment-based drug discovery library and service providers, featuring a two-dimensional scatter plot representation. It highlights the key players in this domain, taking into consideration the supplier power (based on the year of establishment of service provider) and key specifications, such as number of fragment libraries and number of screening techniques.

Chapter 9 provides an analysis highlighting the cost saving potential associated with the use of fragment-based drug discovery approach.

Chapter 10 features an elaborate market forecast analysis, highlighting the likely growth of fragment-based drug discovery market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis [A] type of technique (X-ray crystallography, nuclear magnetic resonance, surface plasmon resonance and other screening techniques), [B] type of service (library screening, fragment screening and fragment optimization), [C] end user (industry players and non-industry players), and [D] key geographical regions (US, Canada, UK, Germany, France, Italy, Spain, rest of Europe, China, Japan, India, and rest of Asia-Pacific / rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

Chapter 11 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented a brief overview of the companies and details of our conversations held with Jean-Yves Ortholand (Co-founder & Chief Executive Officer, Edelris) and Björn Walse (Chief Executive Officer, SARomics Biostructures).

Chapter 12 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the fragment-based drug discovery industry. 

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 14 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Drug Development

3.3. Drug Discovery Process
3.3.1. Target Identification
3.3.2. Target Validation
3.3.3. Hit Generation
3.3.4. Hit-to-Lead
3.3.5. Lead Optimization

3.4. High-Throughput Screening (HTS) and its Limitations

3.5. Fragment-based Drug Discovery (FBDD)
3.5.1. FBDD Strategies
3.5.2. Screening Techniques Used in FBDD

3.6. Challenges Related to FBDD
3.7. Future Perspectives

4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Fragment-based Drug Discovery: List of Library and Service Providers
4.2.1. Analysis by Year of Establishment of Company
4.2.2. Analysis by Company Size and Geographical Location
4.2.3. Leading Library and Service Providers: Analysis by Number of Products
4.2.4. Analysis by Geography
4.2.5. Analysis by Type of Service Offered
4.2.6. Analysis by Type of Technique Used
4.2.7. Analysis by Other Services Offered
4.2.8. Analysis by End User

4.3. Fragment-based Drug Discovery: List of Libraries and Technologies
4.3.1. Analysis by Type of Product

5. COMPANY PROFILES: FRAGMENT-BASED DRUG DISCOVERY LIBRARY AND SERVICE PROVIDERS
5.1. Chapter Overview

5.2. 2bind
5.2.1. Recent Developments and Future Outlook

5.3. Charles River Laboratories
5.3.1. Recent Developments and Future Outlook

5.4. ChemAxon
5.4.1. Recent Developments and Future Outlook

5.5. ComInnex
5.5.1. Recent Developments and Future Outlook

5.6. Creative Biolabs
5.6.1. Recent Developments and Future Outlook

5.7. Creative Biostructure

5.8. CRELUX
5.8.1. Recent Developments and Future Outlook

5.9. Domainex
5.9.1. Recent Developments and Future Outlook

5.10. Evotec
5.10.1. Recent Developments and Future Outlook

5.11. Red Glead Discovery

5.12. SARomics Biostructures

5.13. Shanghai ChemPartner
5.13.1. Recent Developments and Future Outlook

5.14. Sygnature Discovery
5.14.1. Recent Developments and Future Outlook

5.15. Vernalis Research
5.15.1. Recent Developments and Future Outlook

6. PARTNERSHIPS AND COLLABORATIONS
6.1. Chapter Overview
6.2. Partnership Models

6.3. Fragment-based Drug Discovery Services Market: List of Partnerships and Collaborations
6.3.1. Analysis by Year of Partnership
6.3.2. Analysis by Type of Partnership
6.3.3. Analysis by Year of Partnership and Type of Partner
6.3.4. Most Active Players: Analysis by Number of Partnerships
6.3.5. Regional Analysis
6.3.6. Intercontinental and Intracontinental Agreements

7. KEY ACQUISITION TARGETS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Scoring Criteria and Key Assumptions
7.4. Potential Strategic Acquisition Targets in North America
7.5. Potential Strategic Acquisition Targets in Europe
7.6. Potential Strategic Acquisition Targets in Asia-Pacific
7.7. Concluding Remarks

8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Methodology
8.3. Key Parameters
8.4. Competitiveness Analysis: Fragment-based Drug Discovery Library and Service Providers
8.4.1. Fragment-based Drug Discovery Library and Service Providers based in North America
8.4.2. Fragment-based Drug Discovery Library and Service Providers based in Europe
8.4.3. Fragment-based Drug Discovery Library and Service Providers based in Asia-Pacific

9. COST SAVING ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Parameters
9.3. Methodology
9.4. Overall Cost Saving Potential Associated with FBDD, 2020-2030
9.5. Concluding Remarks

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Forecast Methodology
10.3. Global Fragment-based Drug Discovery Market, 2020-2030
10.4. Global Fragment-based Drug Discovery Market: Distribution by Type of Technique, 2020 and 2030
10.4.1. Fragment-based Drug Discovery Market for X-ray Crystallography, 2020-2030
10.4.2. Fragment-based Drug Discovery Market for Nuclear Magnetic Resonance, 2020-2030
10.4.3. Fragment-based Drug Discovery Market for Surface Plasmon Resonance, 2020-2030
10.4.4. Fragment-based Drug Discovery Market for Other Screening Techniques, 2020-2030

10.5. Global Fragment-based Drug Discovery Market: Distribution by Type of Service, 2020 and 2030
10.5.1. Fragment-based Drug Discovery Market for Library Screening, 2020-2030
10.5.2. Fragment-based Drug Discovery Market for Fragment Screening, 2020-2030
10.5.3. Fragment-based Drug Discovery Market for Fragment Optimization, 2020-2030

10.6. Global Fragment-based Drug Discovery Market: Distribution by End User, 2020 and 2030
10.6.1. Fragment-based Drug Discovery Market for Industry Players, 2020-2030
10.6.2. Fragment-based Drug Discovery Market for Non-industry Players, 2020-2030

10.7. Global Fragment-based Drug Discovery Market: Distribution by Geography, 2020 and 2030
10.7.1. Fragment-based Drug Discovery Market in the US, 2020-2030
10.7.2. Fragment-based Drug Discovery Market in Canada, 2020-2030
10.7.3. Fragment-based Drug Discovery Market in the UK, 2020-2030
10.7.4. Fragment-based Drug Discovery Market in France, 2020-2030
10.7.5. Fragment-based Drug Discovery Market in Germany, 2020-2030
10.7.6. Fragment-based Drug Discovery Market in Spain, 2020-2030
10.7.7. Fragment-based Drug Discovery Market in Italy, 2020-2030
10.7.8. Fragment-based Drug Discovery Market in Rest of Europe, 2020-2030
10.7.9. Fragment-based Drug Discovery Market in China, 2020-2030
10.7.10. Fragment-based Drug Discovery Market in Japan, 2020-2030
10.7.11. Fragment-based Drug Discovery Market in India, 2020-2030
10.7.12. Fragment-based Drug Discovery Market in Rest of Asia-Pacific and Rest of the World, 2020-2030

11. EXECUTIVE INSIGHTS
11.1. Chapter Overview

11.2. Edelris
11.2.1. Company Snapshot
11.2.2. Interview Transcript: Jean-Yves Ortholand, Co-founder & Chief Executive Officer

11.3. SARomics Biostructures
11.3.1. Company Snapshot
11.3.2. Interview Transcript: Björn Walse, Chief Executive Officer

12. CONCLUDING REMARKS

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Drug Discovery and Development Timeline
Figure 3.2 Steps Involved in Drug Discovery Process
Figure 3.3 Fragment-based Drug Discovery Process: Fragment to Lead Optimization
Figure 3.4 Strategies in FBDD
Figure 3.5 Computational Fragment-based Drug Design
Figure 3.6 Screening Techniques Used for FBDD
Figure 4.1 Fragment-based Drug Discovery Library and Service Providers: Distribution by Year of Establishment
Figure 4.2 Fragment-based Drug Discovery Library and Service Providers: Distribution by Company Size and Geographical Location
Figure 4.3 Leading Library and Service Providers: Distribution by Number of Products
Figure 4.4 World Map Representation: Distribution by Geography
Figure 4.5 Fragment-based Drug Discovery Library and Service Providers: Distribution by Type of Technique Used
Figure 4.6 Fragment-based Drug Discovery Library and Service Providers: Distribution by Other Services Offered
Figure 4.7 Fragment-based Drug Discovery Library and Service Providers: Distribution by End User
Figure 4.8 Fragment-based Drug Discovery Library and Service Providers: Distribution by Type of Product
Figure 4.9 Fragment-based Drug Discovery Library and Service Providers: Distribution by Library Size
Figure 6.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2020 (till January)
Figure 6.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 6.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership (2015-2020)
Figure 6.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 6.5 Most Active Players: Distribution by Number of Partnerships
Figure 6.6 Partnerships and Collaborations: Regional Distribution
Figure 6.7 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 7.1 Likely Acquisition Targets: Geographical Distribution
Figure 8.1 Competitiveness Analysis: Fragment-based Drug Discovery Library Providers based in North America
Figure 8.2 Competitiveness Analysis: Fragment-based Drug Discovery Screening Service Providers based in North America
Figure 8.3 Competitiveness Analysis: Fragment-based Drug Discovery Library Providers based in Europe
Figure 8.4 Competitiveness Analysis: Fragment-based Drug Discovery Screening Service Providers based in Europe
Figure 8.5 Competitiveness Analysis: Fragment-based Drug Discovery Library Providers based in Asia-Pacific
Figure 8.6 Competitiveness Analysis: Fragment-based Drug Discovery Screening Service Providers based in Asia-Pacific
Figure 9.1 Approval Trend for Small Molecules: Historical Data (2005-2019)
Figure 9.2 Overall Cost Saving Potential of FBDD: Growth Scenarios
Figure 9.3 Overall Cost Saving Potential of Fragment-based Drug Discovery, 2020-2030 (USD Billion)
Figure 10.1 Global Fragment-based Drug Discovery Market, 2020-2030 (USD Million)
Figure 10.2 Global Fragment-based Drug Discovery Market: Distribution by Type of Technique, 2020 and 2030 (USD Million)
Figure 10.3 Fragment-based Drug Discovery Market for X-ray Crystallography, 2020-2030 (USD Million)
Figure 10.4 Fragment-based Drug Discovery Market for Nuclear Magnetic Resonance, 2020-2030 (USD Million)
Figure 10.5 Fragment-based Drug Discovery Market for Surface Plasmon Resonance, 2020-2030 (USD Million)
Figure 10.6 Fragment-based Drug Discovery Market for Other Screening Techniques, 2020-2030 (USD Million)
Figure 10.7 Global Fragment-based Drug Discovery Market: Distribution by Type of Service, 2020 and 2030 (USD Million)
Figure 10.8 Fragment-based Drug Discovery Market for Library Screening, 2020-2030 (USD Million)
Figure 10.9 Fragment-based Drug Discovery Market for Fragment Screening, 2020-2030 (USD Million)
Figure 10.10 Fragment-based Drug Discovery Market for Fragment Optimization, 2020-2030 (USD Million)
Figure 10.11 Global Fragment-based Drug Discovery Market: Distribution by End User, 2020 and 2030 (USD Million)
Figure 10.12 Fragment-based Drug Discovery Market for Industry Players, 2020-2030 (USD Million)
Figure 10.13 Fragment-based Drug Discovery Market for Non-industry Players, 2020-2030 (USD Million)
Figure 10.14 Global Fragment-based Drug Discovery Market: Distribution by Geography, 2020 and 2030 (USD Million)
Figure 10.15 Fragment-based Drug Discovery Market in the US, 2020-2030 (USD Million)
Figure 10.16 Fragment-based Drug Discovery Market in Canada, 2020-2030 (USD Million)
Figure 10.17 Fragment-based Drug Discovery Market in the UK, 2020-2030 (USD Million)
Figure 10.18 Fragment-based Drug Discovery Market in France, 2020-2030 (USD Million)
Figure 10.19 Fragment-based Drug Discovery Market in Germany, 2020-2030 (USD Million)
Figure 10.20 Fragment-based Drug Discovery Market in Spain, 2020-2030 (USD Million)
Figure 10.21 Fragment-based Drug Discovery Market in Italy, 2020-2030 (USD Million)
Figure 10.22 Fragment-based Drug Discovery Market in Rest of Europe, 2020-2030 (USD Million)
Figure 10.23 Fragment-based Drug Discovery Market in China, 2020-2030 (USD Million)
Figure 10.24 Fragment-based Drug Discovery Market in Japan, 2020-2030 (USD Million)
Figure 10.25 Fragment-based Drug Discovery Market in India, 2020-2030 (USD Million)
Figure 10.26 Fragment-based Drug Discovery Market in Rest of Asia-Pacific and Rest of the World, 2020-2030 (USD Million)

List Of Tables

Table 4.1 Fragment-based Drug Discovery: List of Library and Service Providers
Table 4.2 Fragment-based Drug Discovery: List of Drug Developers and Other Non-Industry Players
Table 4.3 Fragment-based Drug Discovery Library and Service Providers: Type of Service Offered
Table 4.4 Fragment-based Drug Discovery Library and Service Providers: Type of Technique Used
Table 4.5 Fragment-based Drug Discovery Library and Service Providers: Other Services Offered
Table 4.6 Fragment-based Drug Discovery Library and Service Providers: End Users
Table 4.7 Fragment-based Drug Discovery: List of Libraries and Technologies
Table 5.1 Fragment-based Drug Discovery Library and Service Providers: List of Profiled Companies
Table 5.2 2bind: Company Snapshot
Table 5.3 2bind: Recent Developments and Future Outlook
Table 5.4 Charles River Laboratories: Company Snapshot
Table 5.5 Charles River Laboratories: Recent Developments and Future Outlook
Table 5.6 ChemAxon: Company Snapshot
Table 5.7 ChemAxon: Recent Developments and Future Outlook
Table 5.8 ComInnex: Company Snapshot
Table 5.9 ComInnex: Recent Developments and Future Outlook
Table 5.10 Creative Biolabs: Company Snapshot
Table 5.11 Creative Biolabs: Recent Developments and Future Outlook
Table 5.12 Creative Biostructure: Company Snapshot
Table 5.13 CRELUX: Company Snapshot
Table 5.14 CRELUX: Recent Developments and Future Outlook
Table 5.15 Domainex: Company Snapshot
Table 5.16 Domainex: Recent Developments and Future Outlook
Table 5.17 Evotec: Company Snapshot
Table 5.18 Evotec: Recent Developments and Future Outlook
Table 5.19 Red Glead Discovery: Company Snapshot
Table 5.20 SARomics Biostructures: Company Snapshot
Table 5.21 Shanghai ChemPartner: Company Snapshot
Table 5.22 Shanghai ChemPartner: Recent Developments and Future Outlook
Table 5.23 Sygnature Discovery: Company Snapshot
Table 5.24 Sygnature Discovery: Recent Developments and Future Outlook
Table 5.25 Vernalis Research: Company Snapshot
Table 5.26 Vernalis Research: Recent Developments and Future Outlook
Table 6.1 Fragment-based Drug Discovery Services Market: List of Partnerships and Collaborations
Table 7.1 North America: Likely Targets for Acquisition
Table 7.2 Europe: Likely Targets for Acquisition
Table 7.3 Asia-Pacific: Likely Targets for Acquisition
Table 9.1 Drug Discovery Steps: Key Parameters
Table 11.1 Edelris: Key Highlights
Table 11.2 SARomics Biostructures: Key Highlights
Table 12.1 Fragment-based Drug Discovery Library and Service Providers: Summary of the Competitive Insights
Table 13.1 Fragment-based Drug Discovery Library and Service Providers: Distribution by Year of Establishment
Table 13.2 Fragment-based Drug Discovery Library and Service Providers: Distribution by Company Size and Geographical Location
Table 13.3 Leading Library and Service Providers: Distribution by Number of Products
Table 13.4 Fragment-based Drug Discovery Library and Service Providers: Distribution by Type of Technique Used
Table 13.5 Fragment-based Drug Discovery Library and Service Providers: Distribution by Other Services Offered
Table 13.6 Fragment-based Drug Discovery Library and Service Providers: Distribution by End User
Table 13.7 Fragment-based Drug Discovery Library and Service Providers: Distribution by Type of Product
Table 13.8 Fragment-based Drug Discovery Library and Service Providers: Distribution by Library Size
Table 13.9 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2020 (till January)
Table 13.10 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.11 Partnerships and Collaborations: Distribution by Year and Type of Partnership (2015-2020)
Table 13.12 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 13.13 Most Active Players: Distribution by Number of Partnerships
Table 13.14 Partnerships and Collaborations: Regional Distribution
Table 13.15 Approval Trend for Small Molecules: Historical Data (2005-2019)
Table 13.16 Overall Cost Saving Potential of Fragment-based Drug Discovery, 2020-2030 (USD Billion)
Table 13.17 Global Fragment-based Drug Discovery Market, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.18 Global Fragment-based Drug Discovery Market: Distribution by Type of Technique, 2020 and 2030 (USD Million)
Table 13.19 Fragment-based Drug Discovery Market for X-ray Crystallography, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.20 Fragment-based Drug Discovery Market for Nuclear Magnetic Resonance, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.21 Fragment-based Drug Discovery Market for Surface Plasmon Resonance, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.22 Fragment-based Drug Discovery Market for Other Screening Techniques, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.23 Global Fragment-based Drug Discovery Market: Distribution by Type of Service, 2020 and 2030 (USD Million)
Table 13.24 Fragment-based Drug Discovery Market for Library Screening, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.25 Fragment-based Drug Discovery Market for Fragment Screening, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.26 Fragment-based Drug Discovery Market for Fragment Optimization, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.27 Global Fragment-based Drug Discovery Market: Distribution by End User, 2020 and 2030 (USD Million)
Table 13.28 Fragment-based Drug Discovery Market for Industry Players, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.29 Fragment-based Drug Discovery Market for Non-industry Players, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.30 Global Fragment-based Drug Discovery Market: Distribution by Geography, 2020 and 2030 (USD Million)
Table 13.31 Fragment-based Drug Discovery Market in the US, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.32 Fragment-based Drug Discovery Market in Canada, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.33 Fragment-based Drug Discovery Market in the UK, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.34 Fragment-based Drug Discovery Market in France, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.35 Fragment-based Drug Discovery Market in Germany, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.36 Fragment-based Drug Discovery Market in Spain, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.37 Fragment-based Drug Discovery Market in Italy, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.38 Fragment-based Drug Discovery Market in Rest of Europe, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.39 Fragment-based Drug Discovery Market in China, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.40 Fragment-based Drug Discovery Market in Japan, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.41 Fragment-based Drug Discovery Market in India, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)
Table 13.42 Fragment-based Drug Discovery Market in Rest of Asia-Pacific and Rest of the World, Conservative, Base, and Optimistic Scenarios, 2020-2030 (USD Million)

Listed Companies

1. 2bind
2. Accelero Biostructures
3. Advanced Chemistry Development (ACD / Labs)
4. Agilent Technologies
5. Allesh Biosciences Labs
6. Altaris Capital Partners
7. Astex Pharmaceuticals
8. AstraZeneca
9. Aunova Medchem
10. Aurora Fine Chemicals
11. Axxam
12. Basilea Pharmaceutica
13. Beactica
14. Bellvitge Biomedical Research Institute (IDIBELL)
15. BioAscent
16. BioBlocks
17. BioPredict
18. BioSolveIT
19. BOC Sciences
20. Boehringer Ingelheim
21. Bruker
22. C4X Discovery
23. Cambridge Crystallographic Data Centre
24. Cambridge MedChem Consulting
25. Carna Biosciences
26. Center for Drug Design and Discovery
27. Centre for Chemical Biology and Therapeutics
28. Charles River Laboratories
29. CHDI Foundation
30. ChemAxon
31. ChemBridge
32. ChemDiv
33. Chemical Computing Group
34. Collaborative Drug Discovery
35. Collidion
36. Columbia University
37. ComInnex
38. Conifer Point
39. CreaGen
40. Creative Biolabs
41. Creative Biostructure
42. CRELUX
43. Creoptix
44. Cresset
45. CrystalsFirst
46. Daiichi Sankyo
47. Danaher
48. Diamond Light Source
49. Discover Drugs
50. Domainex
51. Dong-A ST
52. DyNAbind
53. Edelris
54. Enamine
55. Evotec
56. Exscientia
57. Fidelta
58. Forge Therapeutics
59. ForteBio
60. GE Healthcare Life Sciences
61. Gotham Therapeutics
62. Helmholtz-Zentrum Berlin
63. Heptares Therapeutics
64. Heriot-Watt University
65. Inte:Ligand
66. IOTA Pharmaceuticals
67. Jena Bioscience
68. Jubilant Biosys
69. Key Organics
70. Keymodule
71. Kinetic Discovery
72. Kymab
73. LeadInvent Technologies
74. leadXpro
75. LEO Pharma
76. LG Chem
77. Life Chemicals
78. Ligand Pharmaceuticals
79. Liverpool ChiroChem
80. MAX IV Laboratory
81. Max Planck Institute
82. Maybridge
83. Medicilon
84. Medicines Discovery Catapult
85. Merck
86. Mestrelab Research
87. MilliporeSigma
88. Molecular Cornerstones
89. Molecular Devices
90. NMX Research and Solutions
91. Northwestern University
92. NovaData Solutions
93. NovAliX
94. o2h discovery
95. OMass Therapeutics
96. omicX
97. OpenEye Scientific Software
98. Optibrium
99. Organochem
100. Origenis
101. OTAVAchemicals
102. Otsuka Pharmaceutical
103. PeptiDream
104. Pfizer
105. Pharmacelera
106. Pharmaron
107. PhoreMost
108. Pierre Fabre
109. Plex Pharmaceuticals
110. Plexxikon
111. PMI BioPharma Solutions
112. Prestwick Chemical
113. Profacgen
114. Prosarix
115. Proteros Biostructures
116. Pyxis Discovery
117. QuantumBio
118. Reaction Biology
119. Reaxense
120. Red Glead Discovery
121. RxCelerate
122. SARomics Biostructures
123. Selcia
124. Selvita
125. SensiQ
126. Servier
127. Shamrock Structures
128. Shanghai ChemPartner
129. Sharp Edge Labs
130. Sierra Sensors
131. SilcsBio
132. Silicon Kinetics
133. Sosei Heptares
134. Spanish National Cancer Research Centre (CNIO)
135. SpectralWorks
136. SpiroChem
137. Sprint Bioscience
138. Structure based Design
139. Sygnature Discovery
140. SynphaTec Japon
141. Taisho Pharmaceutical
142. Takeda Pharmaceutical
143. The Wistar Institute
144. TimTec
145. Universitat Autònoma de Barcelona
146. University of Cambridge
147. University of Nottingham
148. Vernalis Research
149. Viva Biotech
150. Vlaams Instituut voor Biotechnologie
151. WuXi AppTec
152. Xtal BioStructures
153. Zastra Innovations
154. Zenobia Fragments
155. ZoBio